Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Transaction Volume: 3,561.261 shares (aggregated).
- Transaction Date: July 14, 2016.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Ms. C Thomas (SVP, HR). This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Performance Share Plan. No material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of a specific equity transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR involved: Ms. C Thomas, SVP, HR.
- Confirm the nature of the transaction: Dividend re-investment under the 2009 Performance Share Plan.
- Note the transaction price of £16.285 and total volume of 3,561.261 shares.
- Understand that this filing does not contain quarterly or annual financial performance data.